LIMINATUS PHARMA, INC. Net Fee Amt
LIMINATUS PHARMA, INC. (LIMN) had Net Fee Amt of $337.98 as of 2026-06-22, per its S-1 filed 2026-06-24.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-24
- 2026-06-22: Net Fee Amt $337.98.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-22 | $337.98 S-1 · filed 2026-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |